From the FDA Drug Label
YUPELRI is a prescription medicine used to treat chronic obstructive pulmonary disease (COPD). YUPELRI is an anticholinergic medicine. Revefenacin, the active component of YUPELRI, is an anticholinergic.
Yupelri (Revefenacin) is a prescription medicine and an anticholinergic used to treat chronic obstructive pulmonary disease (COPD). It works by helping the muscles around the airways in the lungs stay relaxed to prevent symptoms such as wheezing, cough, chest tightness, and shortness of breath 1.
From the Research
Yupelri (revefenacin) is a once-daily, nebulized long-acting muscarinic antagonist (LAMA) medication approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The standard dosage is 175 mcg (3 mL) administered once daily via a standard jet nebulizer connected to an air compressor, as supported by the most recent study 2. Yupelri works by blocking muscarinic receptors in the airways, which helps prevent bronchoconstriction and reduces symptoms like shortness of breath, wheezing, and cough in COPD patients. Unlike other LAMA medications that come in inhalers, Yupelri's nebulized delivery may benefit patients who have difficulty using handheld inhalers properly or those who prefer nebulization. Some key points to consider when prescribing Yupelri include:
- Common side effects include cough, headache, back pain, and worsening of COPD symptoms, as reported in the study 2.
- Patients should be aware that Yupelri is not intended for acute bronchospasm (rescue therapy) and should continue using their short-acting rescue inhalers as needed.
- The medication should be stored at room temperature and protected from light, and patients should rinse their mouth after treatment to prevent dry mouth and potential oral infections.
- Revefenacin has been shown to be effective and safe in clinical trials, with significant improvements in lung function and quality of life, as demonstrated in the study 3.
- The 175 mcg dose of revefenacin has been found to be the most effective dose, with significant improvements in trough FEV1 and peak FEV1, as reported in the study 4. Overall, Yupelri is a valuable treatment option for patients with COPD, particularly those who require or prefer nebulized therapy, as supported by the study 5.